Echo Therapeutics Expands License Agreement with Ferndale Pharma
Echo Therapeutics, Inc. (Nasdaq: ECTE) today announced that it signed an amended license agreement with Ferndale Pharma Group, Inc. ("Ferndale") that grants Ferndale the right to develop, market and sell Prelude for painless, needle-free skin preparation prior to the application of topical 4% lidocaine cream for fast-acting, local dermal anesthesia prior to a wide-range of needle-based medical procedures.
In addition to the original territory of North America and the United Kingdom, the amended license agreement covers South America, Australia, New Zealand, Switzerland and portions of the European Community.
© 2017 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.